跳至主要内容
临床试验/NCT03771092
NCT03771092已完成不适用

CONTROLLED RANDOMIZED PILOT STUDY TO COMPARE THE EFFICACY OF DIFFERENT IRON FORMULATIONS: SUCROSOMAL FERRIC PYROPHOSPHATE, SUNACTIVE Fe AND INTRAVENOUS FERRIC GLUCONATE

University of Palermo0 个研究点目标入组 148 人开始时间: 2015年11月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
148
主要终点
HB

研究概览

简要总结

The purpose of the study is to evaluate the effects of martial therapy, comparing different formulations, sucrosomal ferric pyrophosphate, SunActive®Fe micronized and ferric gluconate and different ways of administration, orally and intravenous, in subjects affected by sideropenic microcytic hypochromic anemia identified by the simultaneous presence of anemia, microcytosis and hypoferremia.

详细描述

Background: Iron deficiency anemia (IDA) still remains universally a worldwide problematics. Anemia is defined as a hemoglobin value <12.0 g/dL (7.45 mmol/L). Management of IDA is based on martial iron supplementation. The purpose of the study is to evaluate the effects of martial therapy, comparing different formulations, sucrosomal ferric pyrophosphate, SunActive®Fe micronized and ferric gluconate and different ways of administration, orally and intravenous, in subjects affected by sideropenic microcytic hypochromic anemia identified by the simultaneous presence of anemia, microcytosis and hypoferremia.

Trial Design, Methods and Findings: Clinical data from 106 outpatients (82.8% female and 17.2% male, mean age 50.4 years) were collected at Department of Internal Medicine, National Relevance and High Specialization Hospital Trust, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy. The study envisaged five arms (2 + 3). At the first two arms were assigned patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized or Lipofer®. At the other three arms were assigned patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized, Lipofer® or with intravenous ferric gluconate infusions according to departmental protocols. The followed methodology is defined in the PROBE project (acronym of Prospective Randomized Open Blinded End-point). The end points will be blinded with respect to the three treatments, as it will be the statistical analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of iron deficiency anemia, microcytic and hypochromic

排除标准

  • •Diagnosis of Celiac Disease
  • •Patients who refuse to sign the informed consent
  • •Clinically relevant cognitive Turbe
  • •Hemodynamic instability defined by the presence of low blood pressure SBP <100 FC> 100
  • •Dyspnea after modest effort worsening over the past 10 days
  • •Oxygen peripheral saturation values <94%
  • •Ischemic heart Recent and / or lower limbs
  • •Acute conditions with subacute or at recruitment

研究组 & 干预措施

Patients with non-severe anemia treated with SunActive®Fe

Experimental

Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized

干预措施: SunActive®Fe (Dietary Supplement)

Patients with non-severe anemia treated with Lipofer®

Experimental

Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®

干预措施: Lipofer® (Dietary Supplement)

Patients with severe anemia with Lipofer®

Experimental

Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®

干预措施: Lipofer® (Dietary Supplement)

Patients with severe anemia with SunActive®Fe

Experimental

Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized

干预措施: SunActive®Fe (Dietary Supplement)

Patients with severe anemia with intravenous ferric gluconate

Experimental

Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols

干预措施: Intravenous ferric gluconate (Dietary Supplement)

结局指标

主要结局

HB

时间窗: Three months

Mean change of hemoglobin concentration at three months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Salvatore Corrao, MD

Professor

University of Palermo

相似试验